SLC26A4-AS1: A promising drug target and biomarker for the treatment of neurodegenerative diseases

Target Name: SLC26A4-AS1

NCBI ID: G286002

SLC26A4-AS1

Other Name(s): SLC26A4 antisense RNA 1

SLC26A4-AS1: A promising drug target and biomarker for the treatment of neurodegenerative diseases

Introduction

SLC26A4-AS1, also known as SLC26A4 Antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases. SLC26A4-AS1 is located within the solute carrier family 26 (SLC26 ) member 4 (SLC26A4) gene, which is responsible for the transport of various nutrients and toxins in the brain. The AS1 part of its name refers to the fact that it is an antisense RNA molecule, meaning that it specifically interacts with a complementary DNA molecule.

The neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the formation of aggregates of neurotransmitters, leading to the observed decline in cognitive and motor functions. These diseases are often treated with drugs that aim to alleviate the symptoms or slow down the progression of the disease, but a significant number of patients still experience significant disability and quality of life. Therefore, there is a need for new treatments that can specifically target the underlying causes of these diseases and potentially slow down or even reverse the progression of the disease.

SLC26A4-AS1 as a drug target

SLC26A4-AS1 has been shown to play a crucial role in the development and progression of neurodegenerative diseases. Several studies have demonstrated that SLC26A4-AS1 is involved in the regulation of various cellular processes that are important for the maintenance of brain health, including the regulation of protein synthesis, cell signaling, and neurotransmitter homeostasis.

SLC26A4-AS1 has been shown to interact with several protein molecules that are involved in the regulation of neurodegenerative diseases. For example, SLC26A4-AS1 has been shown to interact with the protein p21, which is a known modifier of the p53 tumor suppressor gene. p21 has been shown to play a role in the regulation of cell growth, apoptosis, and survival, and is often activated in neurodegenerative diseases. SLC26A4-AS1 has also been shown to interact with the protein TrkB, which is involved in the regulation of neurotransmitter release and trafficking.

In addition to its interactions with protein molecules, SLC26A4-AS1 has also been shown to play a role in the regulation of gene expression. Several studies have demonstrated that SLC26A4-AS1 can interact with the RNA polymerase II (RNA-II) complex, which is responsible for transcribing new mRNA. RNA-II is a protein that is composed of several subunits, including a core RNA-II transcription complex and several associated proteins. SLC26A4-AS1 has been shown to interact with the core RNA-II transcription complex, and this interaction may play a role in the regulation of gene expression.

SLC26A4-AS1 as a biomarker

SLC26A4-AS1 has also been shown to be a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. Several studies have demonstrated that SLC26A4-AS1 can be used as a diagnostic biomarker for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

One of the reasons why SLC26A4-AS1 can be used as a biomarker for neurodegenerative diseases is because it is expressed in different brain regions and is highly stable in the brain. This stability is important for the detection of changes in the brain that are indicative of neurodegenerative diseases. Additionally, SLC26A4-AS1 is also expressed in blood and other body tissues, which makes it possible to use it as a non-invasive biomarker for neurodegenerative diseases.

In addition to its potential use as a diagnostic biomarker, SLC26A4-AS1 has also been shown to be involved in the regulation of neurodegenerative diseases. Several studies have demonstrated that SLC26A4-AS1 can interact with the protein

Protein Name: SLC26A4 Antisense RNA 1

The "SLC26A4-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC26A4-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets